An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers


Deceased

1 INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France
2 Université de Lyon, 69000 Lyon, France
3 Full list of author information is available at the end of the article

© 2015 Blein et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction

Breast cancer is a multifactorial disease with genetic, lifestyle and environmental susceptibility factors. Approximately 15% to 20% of the familial aggregation of breast cancer is accounted for by mutations in high-penetrance susceptibility genes [1-3], such as BRCA1 and BRCA2. Pathogenic mutations in BRCA1 and BRCA2 confer lifetime breast cancer risk of 60% to 85% [4,5] and 40% to 85% [4,5], respectively. Other genomic variations (for example, in genes encoding proteins interacting with BRCA1 and BRCA2) have been identified as modifiers of breast cancer risk and increase or decrease the risk initially conferred by BRCA1 or BRCA2 mutation [6].

BRCA1 and BRCA2 are involved in DNA repair mechanisms, including double-strand break (DSB) repair by homologous recombination [7,8]. DSBs are considered to be among the most deleterious forms of DNA damage because the integrity of both DNA strands is compromised simultaneously. These breaks can lead to genomic instability resulting in translocations, deletions, duplications or mutations when not correctly repaired [9]. Reactive oxygen species (ROS) are one of the main causes of DSBs, along with exposure to ionizing radiation, various chemical agents and ultraviolet light [10].

ROS are naturally occurring chemical derivatives of metabolism. Elevated levels of ROS and downregulation of ROS scavengers and/or antioxidant enzymes can lead to oxidative stress, which is associated with a number of human diseases, including various cancers [11]. The electron transport chain process, which takes place in the mitochondria, generates the majority of ROS in human cells. Variations in the mitochondrial genome have been shown to be associated with metabolic phenotypes and
oxidative stress markers [12]. Mitochondrial dysfunction recently was shown to promote breast cancer cell migration and invasion through the accumulation of a transcription factor, hypoxia-inducible factor 1α, via increased production of ROS [13].

Human mitochondrial DNA (mtDNA) has undergone a large number of mutations that have segregated during evolution. Those changes are now used to define mitochondrial haplogroups. Some of these changes slightly modify metabolic performance and energy production; thus, not all haplogroups have identical metabolic capacities [14]. It has been hypothesized that the geographic distribution of mitochondrial haplogroups results from selection of metabolic capacities driven mainly by adaptation to climate and nutrition [15,16].

Mitochondrial haplogroups have been associated with diverse multifactorial diseases, such as Alzheimer’s disease [17], hypertrophic cardiomyopathy [18], retinal diseases [19] or age-related macular degeneration [20]. Variations in mtDNA have also been linked to several types of cancer, such as gastric cancer [21] or renal cell carcinoma [22]. Interestingly, variations in mtDNA have been linked to several types of female cancers, including endometrial [23], ovarian [24] and breast cancer [25,26]. A recent study underlined the possibility that mtDNA might be involved in the pathogenic and molecular mechanisms of familial breast cancer [27].

The Collaborative Oncological Gene-environment Study [28] (COGS) is a European project designed to improve understanding of genetic susceptibility to breast, ovarian and prostate cancer. This project involves several consortia: the Breast Cancer Association Consortium (BCAC) [29], the Ovarian Cancer Association Consortium [30], the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) [31] and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) [32]. CIMBA is a collaborative group of researchers working on genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers. As part of the COGS project, more than 200,000 single-nucleotide polymorphisms (SNPs) were genotyped for BRCA1 and BRCA2 female mutation carriers on the iCOGS chip, including 129 mitochondrial polymorphisms. The iCOGS chip is a custom Illumina™ Infinium genotyping array (Illumina, San Diego, CA, USA) designed to test, in a cost-effective manner, genetic variants related to breast, ovarian and prostate cancers.

In this study, we explored mitochondrial haplogroups as potential modifiers of breast cancer risk in women carrying pathogenic BRCA1 or BRCA2 mutations. Our study includes females diagnosed with breast cancer and unaffected carriers belonging to CIMBA. We used an original analytic phylogenetics-based approach implemented in a homemade algorithm and in the program ALTree [33,34] to infer haplogroups and to detect associations between haplogroups and breast cancer risk.

**Methods**

**Ethics statement**

A signed informed written consent form was obtained from all participants. All contributing studies involved in CIMBA received approvals from the institutional review committees at their host institutions. Ethical committees that approved access to the data analyzed in this study are listed in Additional file 1.

**BRCA1 and BRCA2 mutation carriers**

Final analyses included 7,432 breast cancer cases and 7,104 unaffected BRCA1 mutation carriers, as well as 3,989 invasive breast cancer and 3,689 unaffected BRCA2 mutation carriers, all belonging to CIMBA. Supplementary specifications regarding inclusion profiles and studies belonging to CIMBA are available in the reports by Couch et al. [35] and Gaudet et al. [36]. All analyses were conducted separately on CIMBA BRCA1 and BRCA2 mutation carriers (abbreviated pop1 and pop2, respectively). Eligible female carriers were aged 18 years or older and had a pathogenic mutation in BRCA1 and/or BRCA2. Women with both BRCA1 and BRCA2 mutations were included in downstream analyses. Data were available for year of birth, age at study recruitment, age at cancer diagnosis, BRCA1 and BRCA2 mutation description and self-reported ethnicity. Women with ovarian cancer history were not excluded from analyses, and they represented 15% and 7% of BRCA1 and BRCA2 mutation carriers, respectively. Information regarding mastectomy was incomplete and was therefore not used as an inclusion or exclusion parameter.

**Genotyping and quality filtering**

Genotyping was conducted using the iCOGS custom Illumina Infinium array. Data from this array are available to the scientific community upon request. Please see [37] for more information. Genotypes were called using Illumina's proprietary GenCall algorithm. Genotyping and quality filtering were described previously [35,36]. Initially, 129 mitochondrial SNPs were genotyped for both BRCA1 and BRCA2 mutation carriers. SNPs fulfilling the following criteria were excluded from downstream analyses: monoallelic SNPs (minor allele frequency = 0), SNPs with more than 5% data missing, annotated as triallelic, or having probes cross-matching with the nuclear genome. Heterozygous genotypes were removed from analyses, and we further filtered out SNPs having more than 5% of heterozygous calls to limit the potential for heteroplasmy affecting our results. We also did not retain SNPs representing private mutations. These mutations are rare, often restricted to a few families, and not sufficiently prevalent in the general population to be included in the reference
mitochondrial evolutionary tree (see below). This last step of filtration yielded 93 and 92 SNPs for the pop1 and pop2 analyses, respectively (see Additional file 2). Only individuals with fully defined haplotypes (that is, non-missing genotypes for the 93 and 92 SNPs selected for pop1 and pop2, respectively) were included in downstream analyses (14,536 and 7,678 individuals, respectively).

**Mitochondrial genome evolution and haplogroup definition**

Analyses were based on the theoretical reconstructed phylogenetic tree of the mitochondrial genome (mtTree) known as PhyloTree [38] (v.15). The mtTree is rooted by the Reconstructed Sapiens Reference Sequence (RSRS). RSRS has been identified as the most likely candidate to root the mtTree by refining human mitochondrial phylogeny by parsimony [39]. Each haplogroup in mtTree is defined by the set of mtDNA SNPs that have segregated in RSRS until today in the mitochondrial genome. Each haplogroup is fully characterized by the 16,569-bp sequence resulting from the application of all the substitutions that are encoded by the corresponding SNPs in the RSRS sequence.

**Haplogroups imputation**

The phylogenetic approach used to infer haplogroups is described in Figure 1. Mitochondrial genome sequences can be reconstructed at each node of mtTree, given the

---

**Figure 1** Simplified representation of the phylogenetic method used to infer haplogroups. (a) Full-length haplotypic sequences are reconstructed at each node of the reference tree. (b) Haplotypes are then restricted to available loci. Sequences of the same color are identical. (c) Unique short haplotypes are matched directly with the corresponding haplogroup. (d) Sequences that match with several haplogroups are associated with their most recent common ancestor haplogroup. RSRS, Reconstructed Sapiens Reference Sequence.
substitutions that have segregated in RSRS. Each haplogroup therefore has a corresponding full-length mitochondrial sequence. However, the full-length mitochondrial sequence is not available in the data, because the iCOGS platform captured only 93 and 92 SNPs for pop1 and pop2, respectively. Thus, for each of the 7,864 nodes of the phylogenetic tree, the corresponding short haplotype (that is, the full-length sequence restricted to available loci) was defined. Some of the short haplotypes are unique, and they can be matched with their corresponding haplogroup directly. However, most of the time, given the small number of SNPs analyzed, several haplogroups correspond to the same short haplotype. Consequently, a unique haplogroup cannot confidently be assigned to each short haplotype. Therefore, each short haplotype was assigned the most recent common ancestor of all the haplogroups that share the same short haplotype. Once this matching was done, short haplotypes were reconstructed in the same way for each individual in our dataset and were assigned the corresponding haplogroup. The accuracy of the method used was assessed by application to a set of 630 mtDNA sequences of known European and Caucasian haplogroups (see Additional file 3).

Association detection
This phylogenetic approach is based on the identification of subclades in the reference phylogenetic tree of the mitochondrial genome differentially enriched for cases and unaffected controls compared with neighboring subclades. We used ALTree [33,34] to perform association testing. ALTree—standing for Association detection and Localization of susceptibility sites using haplotype phylogenetic Trees—is an algorithm used to perform nested homogeneity tests to compare distributions of affected and unaffected individuals in the different clades of a given phylogenetic tree. The objective is to detect if some clades of a phylogenetic tree are more or less enriched in affected or unaffected individuals compared with the rest of the tree. There are as many tests performed as there are levels in the phylogenetic tree. The $P$-value at each level of the tree is obtained by a permutation procedure in which 1,000 permutations are performed. Individual labels (“affected” or “unaffected”) are permuted 1,000 times to see to what extent the observed distribution of affected or unaffected is different from a random distribution. A procedure to correct for multiple testing adapted to nested tests [40] is implemented in ALTree. The objective of ALTree is to detect an enrichment difference at the level of the whole tree. To conserve computational time and resources, only the most significant $P$-value obtained for all tests performed on one tree is corrected.

Handling genetic dependency
ALTree is used to perform homogeneity tests to detect differences in enrichment or depletion of affected or unaffected individuals between clades in the phylogenetic tree. This kind of test can be performed only on independent data. However, because some individuals in the CIMBA dataset belong to the same family, we constructed datasets with genetically independent data by randomly selecting one individual from among all those belonging to the same family and sharing the same short haplotype. To take into account the full variability of our data, we resampled 1,000 times. The results of the analysis pipeline are obtained for each resampling independently and then averaged over the 1,000 resamplings to obtain final results.

Character reconstruction at ancestral nodes
Before the ALTree localization algorithm was launched, ancestral sequences were reconstructed at each internal tree node; that is, short haplotypes were inferred with maximum likelihood at all nodes that were not leaves. We used the software PAML [41] to perform the reconstruction at ancestral nodes using a maximum likelihood method. The phylogeny model used was the general time-reversible model (either GTR or REV).

Localization of susceptibility sites
ALTree also includes an algorithm used to identify which sites are the most likely ones to be involved in the association detected. For each short haplotype observed, the ALTree add-on altree-add-S adds to the short haplotype sequence a supplementary character called $S$, which represents the disease status associated with this short haplotype. Are individuals carrying this short haplotype more often affected or unaffected? $S$ is calculated based on the affected and unaffected counts, the relative proportion of affected and unaffected in the whole dataset, and sensibility parameter $e$. $e$ was set to its default value, which is 1. After $S$ character computation, haplotypes including character $S$ are reconstructed at ancestral nodes. Susceptibility site localization is achieved with ALTree by computing a correlated evolution index calculated between each change of each site and the changes of the character $S$ in the two possible directions of change. The sites whose evolution are the most correlated with the character $S$ are the most likely susceptibility sites.

Selected subclades
The analyses were carried out on the full evolutionary tree. However, the more haplogroups there are at each level, the less statistical power homogeneity tests have. Therefore, analyses were also applied to subclades extracted from the tree. Subclades were defined using counts of individuals in each haplogroup of the clade to maximize statistical power. The chosen subclades
and corresponding affected and unaffected counts are presented in Table 2.

**Statistical analysis**

We quantified the effect associated with enrichment discovered by applying ALTree by building a weighted Cox regression in which the outcome variable is the status (affected or non-affected) and the explicative variable is the inferred haplogroup. Analyses were stratified by country. Data were restricted to the clades of interest. The uncertainty in haplogroup inference was not taken into account in the model. The weighting method used takes into account breast cancer incidence rate as a function of age [42] and the gene containing the observed pathogenic mutation (that is, *BRCA1* or *BRCA2*). Familial dependency was handled by using a robust sandwich estimate of variance (R package `survival`, `cluster()` function).

**Results**

**Haplogroup imputation**

In Additional file 4, absolute and relative frequencies are recapitulated for each haplogroup imputed in *BRCA1* and *BRCA2* mutation carriers. For *BRCA1* mutation carriers, we reconstructed 489 distinct short haplotypes of 93 loci from the genotypes data. Only 162 of those 489 short haplotypes matched theoretical haplotypes reconstructed in the reference mitochondrial evolutionary tree. These 162 haplotypes represented 13,315 of 14,536 individuals. Thus, 91.6% of *BRCA1* mutation carriers were successfully assigned a haplogroup. For *BRCA2* mutation carriers, we reconstructed 350 distinct short haplotypes of 92 loci from our genotype data. Only 139 of those 350 short haplotypes matched theoretical haplotypes reconstructed in the reference mitochondrial evolutionary tree. These 139 haplotypes represented 6,996 of 7,678 individuals. Thus, 91.1% of *BRCA2* mutation carriers were successfully assigned a haplogroup. Because more *BRCA1* than *BRCA2* mutation carriers were genotyped (14,536 vs. 7,678 individuals), we logically observed more distinct haplotypes in *pop1* than in *pop2* (489 vs. 350 haplotypes).

The accuracy of the main haplogroup inference method used was estimated at 82% and reached 100% for haplogroups I, J, K, T, U, W and X. Given the set of SNPs we disposed of, our method has difficulty differentiating between H and V haplogroups (see Additional file 3).

**Association results**

For both populations of *BRCA1* or *BRCA2* mutation carriers, as well as for the full tree as for all selected subclades (see Table 1), we extracted the mean corrected *P*-values for association testing over all resamplings performed (see Table 2). The only corrected *P*-value that remained significant was that obtained for subclade T (abbreviated T*) in the population of individuals of *BRCA2* mutation carriers (*P* = 0.04).

The phylogenetic tree of subclade T (see Figure 2a) contains only three levels; thus, only three tests were performed within this clade. Raw *P*-values were examined to determine at which level of the tree ALTree detects a difference of enrichment in affected or unaffected individuals (see Table 3). Only the *P*-value associated with the test performed at the first level of the tree is significant. We looked more closely at the mean frequencies of affected and unaffected individuals in the tree at this level (see Figure 2b). In the T1a1 subclade, the mean count of affected and unaffected are 32 and 47, respectively. In the T2* subclade, we observed, on average, 217 and 148 affected and unaffected individuals, respectively, whereas in the T subclade, we observed, on average, 13 and 11 affected and unaffected individuals, respectively. The ranges observed for each of these values over the 1,000 resamplings are represented in Figure 2b. On the basis of these observations, we conclude that subclade T1a1 is depleted in affected carriers compared with the neighboring subclades T and T2.

### Table 1 Counts of participants in selected subclades

<table>
<thead>
<tr>
<th>Subclade</th>
<th><em>BRCA1</em> mutation carriers</th>
<th><em>BRCA2</em> mutation carriers</th>
</tr>
</thead>
<tbody>
<tr>
<td>U8</td>
<td>1,458</td>
<td>863</td>
</tr>
<tr>
<td>T</td>
<td>1,243</td>
<td>651</td>
</tr>
<tr>
<td>J</td>
<td>1,270</td>
<td>630</td>
</tr>
<tr>
<td>J1</td>
<td>1,043</td>
<td>513</td>
</tr>
<tr>
<td>H</td>
<td>3,706</td>
<td>1,967</td>
</tr>
<tr>
<td>H1</td>
<td>582</td>
<td>337</td>
</tr>
<tr>
<td>U5</td>
<td>868</td>
<td>458</td>
</tr>
<tr>
<td>X12*3</td>
<td>221</td>
<td>103</td>
</tr>
<tr>
<td>K1a</td>
<td>608</td>
<td>364</td>
</tr>
</tbody>
</table>

**Table 2 Mean corrected *P*-values for association testing with ALTree**

<table>
<thead>
<tr>
<th>Subclade</th>
<th><em>pop1</em> corrected <em>P</em>-value</th>
<th><em>pop2</em> corrected <em>P</em>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full</td>
<td>0.830</td>
<td>0.681</td>
</tr>
<tr>
<td>U8</td>
<td>0.146</td>
<td>0.626</td>
</tr>
<tr>
<td>T</td>
<td>0.285</td>
<td>0.040</td>
</tr>
<tr>
<td>J</td>
<td>0.718</td>
<td>0.112</td>
</tr>
<tr>
<td>J1</td>
<td>0.621</td>
<td>0.150</td>
</tr>
<tr>
<td>H</td>
<td>0.747</td>
<td>0.930</td>
</tr>
<tr>
<td>H1</td>
<td>0.268</td>
<td>0.804</td>
</tr>
<tr>
<td>U5</td>
<td>0.829</td>
<td>0.747</td>
</tr>
<tr>
<td>X12*3</td>
<td>0.416</td>
<td>0.629</td>
</tr>
<tr>
<td>K1a</td>
<td>0.170</td>
<td>0.162</td>
</tr>
</tbody>
</table>

*pop1*, *BRCA1* mutation carrier; *pop2*, *BRCA2* mutation carrier. Bold indicates a significant *P*-value.
Localization results
We performed a localization analysis with ALTree. The correlated evolution index for all non-monomorphic sites observed in short haplotype sequences of subclade T are displayed in Additional file 5. The higher the correlated evolution index, the more likely it is that corresponding sites will be involved in the observed association. Three short haplotype sites numbered 44, 57 and 72 and corresponding to SNPs T988C, G11812A/rs4154217 and G13708A/rs28359178, respectively, clearly distinguish themselves, with correlation index values of 0.390, 0.324 and 0.318, respectively, whereas the correlation index values of all other sites ranged from −0.270 to −0.101. Table 4 shows the details for these three loci.

Effect quantification
The ALTree method is able to detect an association, but cannot to quantify the associated effect. We estimated the risk of breast cancer for individuals with the T1a1 haplogroup compared with individuals with another T subclade haplogroup in the population of BRCA2 mutation carriers using a more classical statistical method, a weighted Cox regression. We found a breast cancer HR of 0.55 (95% CI, 0.34 to 0.88; \( P = 0.014 \)). We also tested haplogroup T1a1 and compared it with other T* haplogroups and the H haplogroup (the main haplogroup in the general population), and we found a breast cancer HR of 0.62 (95% CI, 0.40 to 0.95; \( P = 0.03 \)).

Discussion
We employed an original phylogenetic analytic method, coupled with more classical molecular epidemiologic analyses, to detect mitochondrial haplogroups differentially enriched for affected BRCA1/2 mutation carriers. We successfully inferred haplogroups for more than 90% of individuals in our dataset. After haplogroup imputation, the ALTree method identified T1a1 in the T clade as differentially enriched in affected BRCA2 mutation carriers, whereas no enrichment difference was found for BRCA1 mutation carriers. The T subclade is present in 4% of African populations compared with 11% in Caucasian and Eastern European populations [43]. In our data, the T subclade represented 9.34% of BRCA1 mutation carriers and 9.30% of BRCA2 carriers. The ALTree method also identified three potential breast cancer susceptibility loci in mtDNA. The main goals of using the phylogenetic method we used were to improve statistical power by regrouping subclades according to genetic considerations, to limit the number of tests performed and to precisely quantify this number. ALTree identified three SNPs of interest. Whereas the association we observed could possibly be driven by a single SNP, no difference was observed between multivariate and univariate cox models including the three SNPs identified by ALTree (data not shown).

In this study, we investigated to what extent mtDNA variability modified breast cancer risk in individuals

| Table 3 Non-corrected \( P \)-values by level of phylogenetic tree for subclade T in BRCA2 mutation carriers |
|-----------------|---------------------------------|-----------------|
| Level | Degrees of freedom | Mean of non-corrected \( P \)-value |
| 1 | 2 | 0.02141039 |
| 2 | 6 | 0.14359300 |
| 3 | 8 | 0.22249700 |

Figure 2 Phylogenetic tree of subclade T tested for association with ALTree. (a) Phylogenetic tree of subclade T with all observed haplogroups. A homogeneity test is performed at each level of the tree. (b) First level of the phylogenetic tree of subclade T. Averaged counts, ranges and proportions of affected and unaffected observed in resamplings are indicated below each subclade. T2* represents the entire T2 subclade.
carrying pathogenic mutations in BRCA1/2. A large proportion of breast cancer heritability still remains unexplained today [44]. Different methods exist to study genomic susceptibility to a disease, such as linkage analyses (which identified the BRCA1 and BRCA2 susceptibility genes) or genome-wide association studies (GWASs). However, classical linkage analysis cannot be applied to the haploid mitochondrial genome. Furthermore, commercial GWAS chips available do not adequately capture the majority of mtDNA SNPs. A non-genome-wide and mtDNA-focused approach was required to explore how mtDNA variability influences breast cancer risk. Here we have shown that BRCA2 mutation carriers with the subclade T1a1 have between 30% and 50% less risk of breast cancer than those with other clades, which, if validated, is a clinically meaningful risk reduction and may influence the choice of risk management strategies.

The association we observed among BRCA2, but not BRCA1, mutation carriers may reveal a functional alteration that would be specific to mechanisms involving BRCA2-related breast cancer. Today, it is established that BRCA1- and BRCA2-associated breast cancers are not phenotypically identical. These two types of tumors do not harbor the same gene expression profiles or copy number alterations [45]. Breast cancer risk modifiers in BRCA1/2 mutation carriers have already been identified [46]. However, most of them are specific from one or the other type of mutation carried [47]. It is therefore not surprising that this observation is observed in BRCA2 mutation carriers only.

Our inability to assign haplogroups to 9% of study participants could have three main explanations. First, given the high mutation rate in the mitochondrial genome, observed combinations of mtDNA SNPs might have appeared relatively recently in the general population, and the corresponding haplotypes might not yet be incorporated into PhyloTree. Second, only one genotyping error could lead to chimeric haplotypes that do not exist, although, given the quality of our genotyping data, this is unlikely. Third, the mitochondrial reference evolutionary tree PhyloTree is based on phylogeny reconstruction by parsimony, and, for some subclades, it might be suboptimal, especially for haplogroups relying on few mitochondrial sequences, as is the case for African haplogroups [48]. In cases of uncertainty, the choice we made to assign the most recent common ancestor to the studied haplotype enabled us to improve statistical power without introducing a bias in the detected association. For the association detected between T, T1* and T2* subclades, the haplogroup inference method used did not bias the counts of affected and unaffected individuals in these subclades. More details are presented in Additional file 6. Furthermore, on the basis of the haplogroup inference with our method of 630 European and Caucasian mtDNA sequences whose haplogroup is known, we successfully assigned the correct main haplogroup and subhaplogroup of 100% of sequences belonging to T, T2* and T1a1* haplogroups.

We quantified the effect corresponding to the detected association by using a more classical approach. We built a weighted Cox regression including inferred haplogroup as an explicative variable. However, the uncertainty in haplogroup inference was not taken into account in this model. Nevertheless, based on haplogroup assignment and regrouping performed in clade T, affected and unaffected counts of individuals in this clade were not biased.

With only 129 loci genotyped over the 16,569 nucleotides composing the mitochondrial genome, we certainly did not explore the full variability of mitochondrial haplotypes. A characterization of individual mitochondrial genomes would require more complete data acquisition methods to be used, such as next-generation sequencing. However, next-generation sequencing has its own limits and challenges, because some regions of the mitochondrial genome are not easily mappable, owing to a high homology with the nuclear genome, among other factors, and important bioinformatics treatment is necessary to overcome sequencing technology biases. Finally, even for a relatively short genome of “only” 16,569 bp, mtDNA sequencing of more than 20,000 individuals would represent a major increase in cost relative to genotyping 129 SNPs.

ALTree identified T9899C, G11812A/rs41544217 and G13708A/rs28359178 as three potential susceptibility sites for the discovered association (see Additional file 7). These three SNPs are located in the coding part of genes MT-CO3, MT-ND4 and MT-ND5, respectively. When looking at PhyloTree, T9899C seems to be involved in T1 subclade definition, whereas G13708A and A11812G are involved in T2 subclade definition. Whereas T98899C and

---

**Table 4 Description of loci identified as potential susceptibility sites by ALTree**

<table>
<thead>
<tr>
<th>Site</th>
<th>SNP name</th>
<th>Position</th>
<th>Direction of change</th>
<th>Correlated evolution index</th>
<th>Major allele</th>
<th>Minor allele</th>
<th>MAF in pop2</th>
</tr>
</thead>
<tbody>
<tr>
<td>44</td>
<td>MitoT9900LC</td>
<td>9,899</td>
<td>T → C</td>
<td>0.390</td>
<td>T</td>
<td>C</td>
<td>0.016</td>
</tr>
<tr>
<td>57</td>
<td>rs28359178</td>
<td>13,708</td>
<td>G → A</td>
<td>0.318</td>
<td>G</td>
<td>A</td>
<td>0.111</td>
</tr>
</tbody>
</table>

*MAF, Mean allele frequency; pop2, BRCA2 mutation carrier.*
G11821/rs41544217 are synonymous SNPs, G10398A leads to a change of amino acid in the final protein (from alanine to threonine). These two synonymous SNPs have never been described in a disease context in the literature. G13708A is also known for being a secondary mutation for Leber’s hereditary optic neuropathy (LHON) and multiple sclerosis [49]. Although the role of secondary mutations in LHON is still controversial, G13708A could be associated with impairment of the respiratory chain in this pathology. G13708A has also been described as a somatic mutation in a breast cancer tumor, whereas it was not present in adjacent normal tissue or in blood leukocytes [50]. A high proportion of mitochondrial somatic tumor-specific variants are also known mtDNA SNPs, which is consistent with the hypothesis that tumor cells are prone to acquire the same mutations that segregate into mtDNA by selective adaptation when humans migrated out of Africa and confronted new environments [51]. Interestingly, the germline variant G13708A has already been shown to be inversely associated with familial breast cancer risk (with the same direction of the association), with a breast cancer odds ratio of 0.47 (95% CI, 0.24 to 0.92) [52]. None of these SNPs have been described in the context of ovarian cancer.

The corrected P-value obtained using ALTree in studying clade T is 0.02, which is not highly significant. A replication step should be performed to validate these results. However, it will be difficult to include enough women in this replication step, given the specific profile studied here. In fact, the estimations of BRCA2 pathogenic mutations in the general population range from 0.068% [5] to 0.69% [53]. T1a1 represents only a small percentage of European haplogroups (from 1% to 2%). The number of women who have this association is therefore low. However, women carrying such mutations are confronted with drastic choices regarding the prevention of breast cancer, notably prophylactic mastectomy or complete hysterectomy. If breast cancer risk is really reduced by a factor of 2 for women with T1a1, this could be an important fact to take into account for breast cancer prevention.

Conclusions
This study and our results suggest that mitochondrial haplogroup T1a1 may modify the individual breast cancer risk in BRCA2 mutation carriers. For now, this observation cannot be extended to the general population. Further investigation of the biological mechanism behind the associations we observed may further reinforce the hypothesis that the mitochondrial genome is influential in breast cancer risk, particularly among carriers of BRCA2 mutations, and, if validated, is of a level to influence cancer risk management choices.

Additional files

Additional file 1: Methods used to compute coevolution index.

Additional file 2: Absolute and relative frequencies of imputed haplogroups by population. Table containing absolute and relative frequencies of imputed haplogroups for BRCA1 and BRCA2 mutation carriers.

Additional file 3: Additional details of haplogroups inference results for subclade T. Table containing correlated evolution index for all non-monomorphic sites observed in short haplotype sequences of subclade T.

Additional file 4: List of ethical committees that approved the study and our results suggest that mitochondrial haplogroup T1a1 may modify the individual breast cancer risk in BRCA2 mutation carriers. For now, this observation cannot be extended to the general population. Further investigation of the biological mechanism behind the associations we observed may further reinforce the hypothesis that the mitochondrial genome is influential in breast cancer risk, particularly among carriers of BRCA2 mutations, and, if validated, is of a level to influence cancer risk management choices.

Conclusions
This study and our results suggest that mitochondrial haplogroup T1a1 may modify the individual breast cancer risk in BRCA2 mutation carriers. For now, this observation cannot be extended to the general population. Further investigation of the biological mechanism behind the associations we observed may further reinforce the hypothesis that the mitochondrial genome is influential in breast cancer risk, particularly among carriers of BRCA2 mutations, and, if validated, is of a level to influence cancer risk management choices.
members of participants in the Ontario Familiar Breast Cancer Registry for their contributions to the study; Vilius Rudaitis, Laimonas Grilkevičius, Drs Janis Egilis, Anna Kiltova and Aivaras Stengrevics; the families who contribute to the BRCA-gene mutations and breast cancer in South African women (BMBSA) study; Chun Ding and Linda Steele; Alicia Barroso, Rosario Alonso, Guillermo Pita, Alessandra Viel and Lara della Puppa of the Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Italy; Laura Papi of the University of Florence, Florence, Italy; Monica Barile of the Istituto Eplorativo di Oncologia, Milan, Italy; Liliana Varesco of the IRCCS AOU San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; Stefania Tormassi, Brunella Pilato and Rossanna Lambo of the Istituto Nazionale Tumori “Giovanni Paolo II” – Bari, Italy; Aline Martayan of the Istituto Nazionale Tumori Regina Bena, Rome, Italy; Maria Grazia Tiliberti of the Ospedale di Circolo-Università dell’Insurbia, Varese, Italy; and the personnel of the Cobgent Cancer Genetic Test Laboratory, Milan, Italy.

Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE) Collaborating Centers: coordinating center, Cambridge, UK: Debra Frost, Steve Ellis, Elena Fineberg and Radka Platte; North of Scotland Regional Genetics Service, UK: Zsuzsa Toth, Kay Rizos and Marian Varga; Northern Ireland Regional Genetics Service, Belfast, UK: Patrick Morrison and Lisa Jeffers; West Midlands Regional Clinical Genetics Service, Birmingham, UK: Trevor Cole, Kai-ren Ong and Jonathan Hoffman; South West Regional Genetics Service, Bristol, UK: Alan Donaldson and Margaret James; East Anglian Regional Genetics Service, Cambridge, UK: Marc Tischkowitz, Joan Patterson and Amy Taylor; Medical Genetics Service, Cardiff, UK: Alexandra Murray, Mark T Rogers and Emma McCann; St James’ Hospital, Dublin, and National Centre for Medical Genetics, Dublin, Ireland: M. John Kennedy and David Barton; South East of Scotland Regional Genetics Service, Edinburgh, UK: Mary Porteous and Sarah Drummond; Peninsula Clinical Genetics Service, Exeter, UK: Carolle Brewer, Emma Kiviva, Anne Searle, Selina Goodman and Kathryn Hill; West of Scotland Regional Genetics Service, Glasgow, UK: Rosemarie Davidson, Victoria Murray, Nicola Bradshaw, Lesley Snadden, Mark Longmuir, Catherine Watt, Sarah Gibson, Eishla Haque, Ed Tobias and Alexis Duncan; South East Thames Regional Genetics Service, Guy’s Hospital London: Louise Izatt, Chris Jacobs and Caroline Langman; North West Thames Regional Genetics Service, Harrow, UK: Huw Dorkins; Leicestershire Clinical Genetics Service, Leicester, UK: Julian Banwell; Yorkshire Regional Genetics Service, Leeds, UK: Julian Adlaf and Gemma Serra-Fellu; Cheshire & Merseyside Clinical Genetics Service, Liverpool, UK: Ian Ellis and Catherine Houghton; Manchester Regional Genetics Service, Manchester, UK: D Gareth Evans, Fiona Laloo and Jane Taylor. North East Thames Regional Genetics Service, NE Thames, London: Lucy Side, Alan Male and Cheryl Berlin; Nottingham Centre for Medical Genetics, Nottingham, UK: Jacqueline Eason and Rebecca Collier; Northern Clinical Genetics Service, Newcastle, UK: Fiona Douglas, Oonagh Claber and Irene Jobson; Oxford Regional Genetics Service, Oxford, UK: Lisa Walker, Diane McLeod, Dorothy Halliday, Sarah Durell and Fiona Douglas; Oxford Regional Genetics Service, Sheffield, UK: Jackie Cook, Oliver Quarell and Cathryn Bardsley; South West Thames Regional Genetics Service, London: Shirley Hodgson, Sheila Goff, Glen Brice, Lizzie Winchester, Charlotte Eddy, Vishalaka Tripathi, Virginia Attard and Anna Lehmann; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK: Diana Ercles, Annette Linstead, Gillian Crayford, Donna Milsome and Sarah Smalley; and JoEllen Weaver and Dr Betsy Bove for their technical support.

Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO) study: National Cancer Genomics Network UNICANCER Genetic Group, France; GEMO Collaborating Centers: coordinating centers, Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon – Centre Léon Bérard, and équipe Génétique du cancer du sein, Centre de Recherche en Cancérologie de Lyon; Olga Sinilnikova, Sylvie Mazoyer, Francesca Damilotta, Laure Barjouh, Carole Verney-Prié, Alain Calender, Sophie Giraud and Mélanie Léone; and Service de Génétique Oncologique, Institut Curie, Paris: Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Claude Houadayer, Virginie Moncoutoir, Muriel Belotti, Carole Tirapo, Antoine de Pauc, Institut Gustave Roussy, Villejuif; France; Brigite Bressac-de-Pallères and Olivier Caron; Centre Jean Perrin, Clermont-Ferrand, France: Yves-Jean Bignon and Nancy Uthhammer; Centre Léon Bérard, Lyon, France: Christine Lasset, Valérie Bonadona and Sandrine Handallou; Centre Français Baessesse, Caen, France: Agnès Hardouin and Pascaline Berthet; Institut Paoli Calmettes, Marseille, France: Hagay Sobol, Violaine Bourdon, Tetsuo Noguchi, Audrey Remenieras and François Esingier; Centre Hospitalier Régional Universitaire Arnaud-de-Villeneuve, Montpellier, France: Isabelle Couperie and Pascal Pujo; Centre Oscar Lambret, Lille, France: Jean-Philippe Peyrat, Joëlle Fournier, Françoise Révillon, Philippe Vennin and Claude Adenis; Hospital René Huguenin, Institut Cure, Saint-Cloud, France: Etienne Bouleau, Rosine Lefevre, Liliane Demange and Catherine Noguère; Centre Paul Strauss, Strasbourg, France: Danièle Müller and Jean-Pierre Fricker; Institut Bergonié, Bordeaux, France: Emmanuelle Barouk-Simonet, François Bonnet, Virginie Bubien, Nicolas Severn and Michel Longy; Institut Claudius Regaud, Toulouse, France: Christine Toulas, Rosine Guimbaud, Vanessa Loge and Viviane Feillet, Centre Hospitalier Universitaire de Grenoble, Grenoble, France: Dominique Leroux, Hélène Dreyfus, Christine Rebsichung and Magalie Peysselon; Centre Hospitalier Universitaire de Dijon, Dijon, France: Fanny Corin and Laurence Faire; Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France: Fabienne Prieur, Marine Lebrun and Caroline Kientz; Hôtel Dieu Centre Hospitalier, Chambéry, France: Sandra Ferr Ferret, Centre Antoine Lacassagne, Nice, France: Marc Freixanet; Centre Hospitalier Universitaire de Utrecht, Leiden, the Netherlands: CVB Blein, and Heide Luijkx; Centre Hospitalier Universitaire de Nantes, Nantes, France: Capucine Delnatté; Centre Hospitalier Universitaire de Bretonneau, Tours, France: Isabelle Mortembreuse; Groupe Hospitalier Pitié-Salpetrière, Paris: Florence Coulet, Christelle Colas and Florent Soubrier; Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre-les-Nancy, France: Johanna Sokolowska and Myriam Brnonner; Centre Hospitalier Universitaire de Paris: Carole Girard, Jerome Hugues, France: Marie-Agnès Collonge-Rame and Alexandre Damette, Creighton University, Omaha, USA: HE, Tonya T Lynch and Carrie L Snyder; the technical support of Ilse Coene en Brecht Crombee; and the investigators of the Australia New Zealand Gynaecological Oncology Group (ANZOGO). We acknowledge Alicia Tosar for her technical assistance; Taru A Musaren, Drs Carl Blomqvist and Kismarin Aaltonen, and registered nurses Iija Erikilä and Virpi Palosuo for their help with the Helsinki Breast Cancer Study (HEBCS) data and samples.

The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON): collaborating centers: Netherlands Cancer Institute, Amsterdam: MA Rookoo, FBL Hogervorst, FE van Leeuwen, S Verhoef, MK Schmidt, JL de Lange and R Wijnen; Erasmus Medical Center, Rotterdam, the Netherlands: JIM Collée, AMM van den Ouweland, MJ Hoonwing, C Seynevea, CHM van Deuzen and IM Obdeijn; Leiden University Medical Center, Leiden, the Netherlands: CJ van Asperen, JT Wijnen, RAEM Tollenaar, P Devilee and TCTEF van Cronenborg; Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands: CM Kets and AR Mensenkamp; University Medical Center Utrecht, Utrecht, the Netherlands: MGEM Ausems and RB van der Luijt; Amsterdam Medical Center, Amsterdam: CM Aalst and TAM van Oo; VU University Medical Center, Amsterdam: JIP Gille, Q Wastorf and HEJ Meijers-Heijboer; University Hospital Maastricht, Maastricht, the Netherlands: EB Gómez-Garcia and MJ Blok; University Medical Center Groningen, Groningen, the Netherlands: JC Oosterwijk, AH van der Houw, MJ Mounts and GH de Bock; The Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, the Netherlands: HF Vasen; The Netherlands Cancer Registry; S Siedling: The Dutch Pathology Registry (PALGA): LKH Overbeek; Hong Kong Sanatorium & Hospital for their continual support; Janos Papp, Tibor Vaszkó, Aniko Bozsik, Timea Pocza, Judit Franko, Maria Balogh, Janis Eglitis, Anna Krilova and Aivars Stengrevics; the families who contribute to BRCA-gene studies and samples.

We acknowledge Alicia Tosar for her technical assistance; Taru A Musaren, Drs Carl Blomqvist and Kismarin Aaltonen, and registered nurses Iija Erikilä and Virpi Palosuo for their help with the Helsinki Breast Cancer Study (HEBCS) data and samples.
Czech Republic); Michal Zikan, Petr Pohlreich and Zdenek Kleibl (Oncogenecologic Center and Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic); Anne Lincoln and Lauren Jacobs; the National Israeli Cancer Control Center (NICC) National Familial Cancer Consultation Service team led by Sara Dishon; the laboratory team led by Dr Flavio Lejbkowicz; and the research field operations team Mla Pinchev; members and participants in the Ontario Cancer Genetics Network for their contributions to the study. Leigha Senter, Kevin Sweet, Caroline Caven and Michelle O’Connor were instrumental in accrual of study participants, ascertainment of medical records and database management; The Ohio State University Human Genetics Sample Bank; the Merav Breast Center team at the Sheba Medical Center, Åke Borg, Hilak Olsson, Helena Jerntorp, Karin Henriksson, Katja Harbst, Maria Soller and UK Krestoferson; Sahlgrenska University Hospital, Gothenburg, Sweden: Anna Ötterholm, Margareta Nordling, Per Kafkas and Zakaria Einbinger; Stockholm and Karolinska University Hospital, Stockholm: Anna von Wachenfeldt, Annelie Liljegren, Annika Lindblom, Brita Arver, Gesa Barbany Bustrin and Johanna Rannta; Umeå University Hospital, Umeå, Sweden: Beatrice Melin, Christina Edwinsdotter Adorno and Monica Emanuelsson; Uppsala University, Uppsala, Sweden: Hans Gustafsson and Maria Hellström Pigger and Ander Rosenquist; Linköping University Hospital, Linköping, Sweden: Marie Stenmark-Askmalm and Sigrun Liedgren; Cecilia Zvocer, Qin Niu, and physicians, genetic counselors, research nurses and staff of the Comprehensive Cancer Risk and Prevention Clinic of University of Chicago Medicine, Chicago, IL, USA; for their contributions to this resource; Joyce Seldon, MSGC, and Lorna Kwan, MPH; Dr Robert Nussbaum and the following genetic counselors: Beth Crawford, Kate Lonanger, Julie Mak, Nicola Stewart, Robin Lee, Amie Blanco and Peggy Conrad; Salina Chan; Paul DP Pharaoh, Simon Gayther, Susan Ramus, Carole Pye, Patricia Harrington and Eva Wozniak for their contributions to the UK Familial Ovarian Cancer Registry (UFOCR); Geoffrey Lindeman, Marlinn Harris, Martin Delatycki of the Victorian Familial Cancer Trials Group; and Sarah Sawyer, Rebecca Driessen and Ella Thompson.

Funding

Higher-level funding: The COGS project is funded through a European Commission Seventh Framework Program grant (agreement number 223175: HEALTH-F2-2009-233175). The COGMA data management and data analysis were supported by Cancer Research UK grants C12292/A11174 and C1287/A11018. SH is supported by a National Health and Medical Research Council (NHMRC) program grant (to GCT).

Individual researcher support: ACA is a Cancer Research UK Senior Cancer Research Fellow (C12922/A11174), DFE is a Principal Research Fellow of Cancer Research UK GC, MCS and IC are supported by the National Health and Medical Research Council (NHMRC), BK holds an American Cancer Society Early Detection Professorship (SOJP-06-258-01-COUN). MHG and PLM were supported by funding from the Intramural Research Program of the National Cancer Institute, National Institutes of Health. OIO is an American Cancer Society Clinical Research Professor. JS is Chairholder of the Canada Research Chair in Oncogenetics.

Funding of constituent studies: The Breast Cancer Family Registry (BCFR) was supported by grant UM1 CA164920 from the National Cancer Institute, National Institutes of Health. The content of this article does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCRF, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government or the BCFR. The Baltic Familial Breast Ovarian Cancer Consortium (BFBOCC) is partly supported by Lithuania (BFBOCC-LT): Research Council of Lithuania grant LIG-07/2012; BFBOCC-LV (Latvia) is partly supported by LSC grant 10.0010.08 and in part by a grant from the European Social Fund number 2009/020/1OP1.1.2.0/09/APIA/IAA/016 and the Liepāja City Council, Liepāja, Latvia; Beth Israel Deaconess Medical Center Cancer Center is supported by the Breast Cancer Research Foundation; BRCA-gene mutations and breast cancer in South African women (BMBSA) was supported by grants from the Cancer Association of South Africa (Cansa) to Elizabeth J van Rensburg; SLN (Beckman Research Institute, City of Hope, Duarte, CA, USA) was partially supported by the Morris and Horowitz Families Cancer Research Chair in Oncogenetics and the Spanish National Cancer Research Center (Centro Nacional de Investigaciones Oncológicas (CNIO)) was partially supported by the Spanish Association against Cancer (Asociación Española Contra el Cáncer AECC08), Thematic Network Cooperative Research in Cancer (Red Temática Investigación Cooperativa en Cáncer (RTICC), Centro de Investigación Cáncer, Salamanca, Spain) RTICC 06/0020/1066, Spanish Ministry of Science and Innovation grants FIS PI08 1120 (Fondo de Investigación Sanitaria (FIS)) and SAF2010-20493, and the Fundación Mutua Madrileña (FMMA); the City of Hope Clinical Cancer Genetics Community Network and the Hereditary Cancer Research Registry (COH-GCRR), supported in part by award number ROCA153828 (Principal Investigator: JNM) from the National Cancer Institute and the Office of the Director, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Consortium Stu Itali an i tumori Ereditari Alle Mammelle, Italy (CONSIT Team): Funds from Italian citizens who allocated the “5 × 1,000” share of their tax payment in support of the Fondazione RICCS Istituto Nazionale Tumori, according to Italian laws (Istituto Nazionale dei Tumori (INT) institutional strategic project “5 × 1,000”) (to SM); the Italian Association for Cancer Research (AIRC) (to LO); National Centre for Scientific Research “Demokritos” has been cofinanced by the European Union (European Social Fund (ESF)) and Greek national funds through the “Education and Lifelong Learning” operational program of the National Strategic Reference Framework (NSRF) – Research Funding Program of the General Secretariat for Research and Technology: ARISTEA “Heracleitus II: Investing in knowledge society through the European Social Fund”; the DFKZ study was supported by the Deutsches Krebsforschungszentrum (DFKZ); the Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE) is supported by grants C1287/A11190; DGE and FL are supported by a National Institute for Health Research (NIHR) grant to the Biomedical Research Centre, Manchester, UK; the investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London; RE and EB are supported by Cancer Research UK grant CS047/A8385; Kansas University Medical Center: The authors acknowledge support from The University of Kansas Cancer Center (P30 CA168524) and the Kansas Bioscience Authority Eminent Scholar Program; AKW was funded by grants SU01 CA113916 and R01 CA140323 and by the Chancellors Distinguished Chair in Biomedical Sciences Professorship; The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by German Cancer Aid (grant 109076) (to RKS) and by the Center for Molecular Medicine Cologne (CMMC); GC-HBOC is deeply grateful to Dr Sabine Preiser-Adam for providing information and samples; the GEMO Study was supported by the Ligue Nationale Contre le Cancer; the Association “Le cancer du sein, parlons-en!” Award; and the Canadian Institutes of Health Research for the CHFR Team in Familial Risks of Breast Cancer program. G-FAST: KDL is supported by GOA grant (grant 10/GOA/019) (Ghent University) and spearhead funding from Ghent University Hospital; the Gynecologic Oncology Group (GOG) was supported by National Cancer Institute grants to the GOG Administrative Office and Tissue Bank (grant CA 27469), the GOG Statistical and Data Center (grant CA 37517) and GOG’s Cancer Prevention and Control Committee (grant CA 101169); HSCC was supported by grants R01/03698/0016 and 12/00339 from Instituto de Salud Carlos III (ISCIII), Madrid, Spain; partially supported by European Regional Development Fund (Fonds européen de développement régional (FEDER): funds; the Helsinki Breast Cancer Study (HEBCS) was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society and the Sigrid Juselius Foundation; HEBON was supported by the Dutch Cancer Society grant NK01999-1954; NK0204-398B and NK0207-3756, the Netherlands Organization of Scientific Research grant NWO 11090024, the Pink Ribbon grant 110005 and Biobanking and Molecular Resource Infrastructure (BIBMIR) grant NWO 184.021.007/CP46; HEBON thanks the registration teams of the Comprehensive Cancer Centre Netherlands and Comprehensive Centre South (together the Netherlands Cancer Registry) and PALGA (Dutch Pathology Registry) for part of the data collection; the High Risk Breast Cancer Program (HRBPC) is supported by the Hong Kong Hereditary Breast Cancer Family Registry and the Dr Ellen Li Charitable Foundation, Hong Kong; the Hungarian Breast and Ovarian Cancer Study (HUNBOCS) was supported by Hungarian Research and Technological Innovation Fund (KIA)/Hungarian Scientific Research Fund (Onkológos Tudományos Kutatási Alapprogramok (OTKA) research grants KIA-OTKA CK-80745 and KIA-OTKA K-112228; Institut Català d’Oncología (ICO): contract grant sponsor: Asociación Española Contra el Cáncer, Spanish Health Research Foundation; Ramón Areces Foundation; Instituto de Salud
Carlos III (ISCIII); Catalan Health Institute; and Autonomous Government of Catalonia; contract grant numbers ISCIII 2010/0200105, 01/002483, 01/010422, 01/00748, 01/3/00285, 01/3/00189 2009GR290 and 01/3/00189 2009GR283; the International Hereditary Cancer Center (Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland) was supported by project PBZ-KBN_122/P05/2004; Landslipt; the National University Hospital of Iceland was supported by the Icelandic Association “Walking for Breast Cancer Research” and by the Landslipt University Hospital Research Fund; the Interdisciplinary Health Research Internal Team Breast Cancer Susceptibility Study (INHERIT) was supported by the Canadian Institutes of Health Research (CIHR) for the “CIHR Team in Familial Risks of Breast Cancer” program, Canadian Breast Cancer Research Alliance grant O19511 and Ministry of Economic Development, Innovation and Export Trade grant PSR-SIRI-701; the Instituto Oncologico Veneto Hereditary Breast and Ovarian Cancer Study (IOV-HBOCS) is supported by the Ministero della Salute and a “> 1,000” Instituto Oncologico Veneto grant; the Portuguese Oncology Institute–Porto Breast Cancer Study (IPBPCS) was supported in part by Liga Portuguesa Contra o Cancro; KcInLab is supported by a grant from the National Institutes of Health; OMICRON (CA116201), a US Department of Defense Ovarian Cancer Idea award (WB1XWHM-10-1-0341), a grant from the Breast Cancer Research Foundation, a generous gift from the David F and Margaret T Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation; McGill University Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry of Economic Development, Innovation and Export Trade; Modifier Study of Quantitative Effects on Disease (ModSQaud) was supported by the Ministry of Health of the Czech Republic to Maxaryk Memorial Cancer Institute (MH CZ – DO) (MMC) 00209805) and by the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/ 2.1.00/03.0101) (to LF), and by Charles University in Prague project UMEZ204024-M2; Memorial Sloan Kettering Cancer Center (MSKCC) is supported by grants from the Breast Cancer Research Foundation and Robert and Kate Niehaus Clinical Cancer Genetics Initiative; National Cancer Institute; National Institutes of Health; The research of MHG and PLM was supported by Cancer Research UK (to Paul DP Pharoah); the University of Pennsylvania: National Cancer Registry (UKFOCR) was supported by a project grant from Cancer Research UK (to Paul DP Pharoah); the University of Pennsylvania: National Institutes of Health (NIH) grants R01 CA102776 and R01 CA083855; the Breast Cancer Research Foundation; the Susan G Komen for the Cure, Basser Center for BRCA; Victorian Familial Cancer Trials Group (VFCTG); Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation; The Women’s Cancer Program (WCP) at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, is funded by the American Cancer Society Early Detection Professorship (SIO-P-06-258-01-COUN).

GEMO Study: National Cancer Genetics Network UNICANCER Genetic Group, France.

The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) coordinating center: Netherlands Cancer Institute, Amsterdam.

Author details
1INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche in Cancérologie de Lyon, Lyon, France. 2Univérsité de Lyon, 69000 Lyon, France. 3Univérsité Lyon 1, 69100 Villeurbanne, France. 4UMR CNRS 5558, Laboratoire de Biometrie et Biologie Evolutive (LBBE), “Biometrie et Biologie Evolutive”, Université Claude Bernard Lyon 1, Bâtiment Gélogor Mendel 43 boulevard du 11 novembre 1918, 69622 Villeurbanne, cedex, France. 5Univérsité Grenoble Alpes, UMR 5217, Laboratoire d’Informatique de Grenoble (LIG), équipe-projet Multi-programmation et Ordonnancement sur ressources pour les Applications Interactives de Simulation (MOAIS), 38041 Grenoble, France. 6INRIA Rhône-Alpes, équipe-projet MOALIS, 38334 Saint Ismier, Cedex, France. 7The New York Genome Center (NYGC), and the New York Genome Center, City of Hope National Medical Center, Duarte, CA 91010, USA. 8The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, USA. 9The American Cancer Society Early Detection Professorship (SIO-P-06-258-01-COUN).

Reference
[1] INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche in Cancérologie de Lyon, Lyon, France. 2Univérsité de Lyon, 69000 Lyon, France. 3Univérsité Lyon 1, 69100 Villeurbanne, France.
University, al Powstancow Wlkp 72, 70-111 Szczecin, Poland. 146)Institute for Research on Depression and Cognition, Istituto di Ricerche Farmacologiche "Mario Negri", 20158 Milan, Italy. 147)Institute for Research and Education in Science, 3200 P St NW, Washington, DC 20007, USA. 148)Department of Medical Oncology, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. 149)Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, 420 W 12th Avenue, Columbus, OH 43210, USA. 150)Department of Obstetrics and Gynecology, Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Rua de Jorge Vfeto Ferreira 228, 4050-313 Porto, Portugal. 151)Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, 546 Pine Avenue West, Montreal, QC H3J 1M2, Canada. 152)Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 153)Department of Health Sciences Research, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA. 154)Dana-Farber Cancer Institute, National Institutes of Health, Building 31, Room 4809, 31 Center Drive, MSC 2152, 9000 Rockefeller Pike, Bethesda, MD 20892-2152, USA. 155)Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. 156)Clinical Genetics Research Laboratory, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. 157)Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Universitätssklinik für Frauenheilkunde, AKH – Wien, Währinger Gürtel 18-20, 1090 Vienna, Austria. 158)Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 159)National Israeli Cancer Control Center and Department of Community Medicine and Epidemiology, Clalit Health Services Carmel Medical Center, 34361 Haifa, Israel. 160)Bruce and Ruth Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, 2 Horev Street, 31096 Haifa, Israel. 161)Clinical Genetics Laboratory, University of Toronto, Medical Sciences Building, 6th Floor, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada. 162)Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael’s Hospital, 209 Victoria Street, Toronto, ON M5B 1T8, Canada. 163)Ontario Cancer Genetics Network, Cancer Care Ontario, 620 University Avenue, Toronto, ON M5G 2L7, Canada. 164)Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex, 600 University Avenue, Toronto, ON M5G 1X5, Canada. 165)Department of Molecular Genetics, University of Toronto, Medical Science Building, Room 436B, 1 King’s College Circle, Toronto, ON M5S 1A8, Canada. 166)Department of Human Cancer Genetics, 1093 Biomedical Research Tower, 460 West 12th Avenue, Columbus, OH 43210, USA. 167)Department of Internal Medicine, The Ohio State University Wexner Medical Center, North Doan Tower, 395 West 12th Avenue, Columbus, OH 43210, USA. 168)Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Wexner Medical Center, 1093 Biomedical Research Tower, 460 West 12th Avenue, Columbus, OH 43210, USA. 169)Department of Clinical Genetics, Aalberse Bos, 11, NL-2132 VNH Eindhoven, The Netherlands. 170)Cancer Research Institute 21 C, 6000 Aarhus N, Denmark. 171)Laboratorio di Genetica Oncologica, Divisione di Anatomia Patologica e di Diagnostica Molecolare ed Ultrassonografica, Azienda Ospedaliero Universitaria Pisana – Ospedale S Chiara, via Roma 67, 56126 Pisa, Italy. 172)Sheba Laboratory of Molecular Genetics, The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Ramat Gan, 52651 Tel Aviv, Israel. 173)Department of Oncology, Ryerson University, 33101 Safran, Israel. 174)Department of Cancer Genetics, Karolinska University Hospital, Solna L802, SE-171 76 Stockholm, Sweden. 175)Oncology, Department of Radiation Sciences, Umeå University, SE-901 87 Umeå, Sweden. 176)Department of Oncology-Pathology, Karolinska University Hospital, K7, Afslutningsmottagningen, Radiumhemmet, 171 76 Stockholm, Sweden. 177)Division of Oncology and Pathology, Department of Clinical Sciences, Lund University Hospital, Bangatan 2B, SE-221 85 Lund, Sweden. 178)Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden. 179)Center for Clinical Cancer Genetics and Global Health, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA. 180)Department of Medicine and Genetics, University of California, San Francisco, CA, USA. 181)Department of Preventive Medicine, Keck School of Medicine of University of Southern California, 1441 Eastlake Avenue, Norris Comprehensive Cancer Center, NOR-4435, Los Angeles, CA 90089-9175, USA. 182)Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, 3535 Market Street, Suite 750, Philadelphia, PA 19104-3309, USA. 183)Department of Epidemiology and Biostatistics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, 3535 Market Street, Suite 750, Philadelphia, PA 19104-3309, USA. 184)Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1354, PO Box 301439, Houston, TX 77230-1439, USA. 185)Sir Peter MacCallum Department of Oncology, Familial Cancer Centre, Peter MacCallum Cancer Centre, level 3, St Andrews Place, East Melbourne, VIC 3002, Australia. 186)Sir Peter MacCallum Department of Oncology, The University of Melbourne, Level 5, 161 Barry Street, Parkville 3010 VIC, Australia. 187)Women’s Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA. 188)Servicio de genética oncológica, Institut Curie, Insenr U930, 26 rue d’Ulm, 75248 Paris, France. 189)Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, 15 rue de l’Hôpital de médecine, 75006 Paris, France. 190)Génétique médicale, Faculté de Médecine Lyon Est, Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69373 Lyon, Cedex 08, France. 191)Institut National du Cancer (INCa), La Fondation Synergie Lyon Cancer, Centre Léon Bérard, 28 rue Laineine, 69008 Lyon, Cedex 08, France. 192)Department of Laboratory Medicine and Pathobiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 193)Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA. 194)Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon – Centre Léon Bérard, 69373 Lyon, Cedex 08, France. 195)Clinical Cancer Genetics Community Research Network, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA.

Received: 17 September 2014 Accepted: 27 March 2015

Published online: 25 April 2015

References


